We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Xenetic Bio | XEN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.00 | 6.00 |
| Top Posts |
|---|
Posted at 05/10/2017 18:03 by corrientes Broker saying 'XEN' could reach $10,but any research not in public domain yet. |
Posted at 22/8/2016 02:43 by buywell3 Re post 1341 and 1342Note the references to Peter Laing of excivion ltd Regards what he has previously achieved at Lipoxen ( which was the old name for Xenetic Biosciences when it was based in the UK ) Check out his achievements were and are now. They are set to earn $'s for XEN and this new deal re Zika could now add to that see So it looks a good tie up/deal pre floatation to me Track Record of Invention Peter Laing, CEO, has a strong track record of invention that has given rise to notable licensing deals with major pharma and biotech companies. As a Lecturer in Immunology at the Univesity of Nottingham he filed one of the first patents on luminescent DNA sequencing; at Peptide Therapeutics plc (later Acambis) as Director of Research he pioneered 'Molecular Vaccine Design' patenting peptide mimics of the capsular polysaccharide of the group-B meningococcus as vaccine immunogens; at Lipoxen plc he was responsible for development of the 'Virtual Conjugate Vaccine' that was licensed to Serum Institute of India Ltd for a 14-component pneumococcal vaccine (wherein liposomal formulation takes the place of chemical conjugation); at Lipoxen (now Xenetic) as Chief Operating Officer he was also responsible for their 'Co-Delivery' technology which exploits DNA and protein representations of an antigen in the selfsame particle effecting dramatic improvements in vaccine potency (allowing single-dose), exemplified with influenza and hepatitis-B vaccines. At Lipoxen he also developed long-acting versions of factor-VIII in collaboration with Baxter, and a next-generation EPO (ErepoXen) for anaemia, now in phase-III. At United Therapeutics Corp/Europe Ltd he was in charge of their hepatitis-C programme and an inventor of diagnostic and therapeutic patents in the field of flaviviruses, notably UV4B - an oral broad-spectrum antiviral agent now licensed to Emergent for dengue. These finely tuned inventive skills are now dedicated to Excivion in pursuit of its New Pharmaceutical Model. |
Posted at 17/3/2016 17:07 by buywell2 Valeant would have been better off buying XEN than the last 3 companies it bought |
Posted at 12/11/2015 23:56 by buywell3 If Baxter thought XEN technology worthy of investing their Factor V111 future onPlus the Russian Government putting the future of quite a proportion of their own biotech expansion plans Plus the largest vaccine manufacturer in India also paying for and carrying out clinical trials on a drug which will soon be used across India Then one would imagine USA investors will be wanting in when XEN lists in NASDAQ on the back of further positive clinical trials news plus NEW Orphan drug developments which should ONLY benefit XEN shareholders I would imagine the float price will be in excess of 1.5$ Wonder if the knockers/prats agree ? |
Posted at 12/1/2014 18:52 by ashthorpedo General Sales and Leasing Inc will change it name to Xenetic Biosciences Inc on or around 14 January 2014.hxxp://www.4-traders General Sales and Leasing Inc : GENERAL SALES & LEASING, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations During the fourth quarter of our fiscal year ended August 31, 2013, we entered into discussions with Xenetic Biosciences plc ("XEN") regarding a potential all share offer for the entire issued and to be issued share capital of XEN (the "Acquisition"). On November 12, 2013, we reached an agreement on the terms of a recommended proposal for the Acquisition under which we will acquire the entire issued and to be issued share capital of XEN. As XEN is a UK based company trading on the AIM London Stock Exchange, the Acquisition is to be effected by means of a scheme of arrangement (the "Scheme") under Part 26 of the Companies Act in the UK by filing a Part 8 Claim with the High Court in London (which was filed on or about November 21, 2013). The Scheme needs to be approved by both 75% of the shareholders of XEN as well as the High Court in London (after a determination of fairness of the transaction) before becoming effective. On December 17, 2013, XEN announced that a majority in number of Xenetic Shareholders who voted (either in person or by proxy), representing 99.9% per cent by value of all Xenetic Shares held by such Xenetic Shareholders, voted in favor of the resolution to approve the Scheme. In addition, a special resolution to facilitate the implementation of the Scheme was passed by the requisite majority of the XEN shareholder votes cast in person or by proxy. On November 12, 2013, as part of the Scheme, we also entered into an Agreement of Conveyance, Transfer and Assignment of Subsidiaries and Assumption of Obligations with our largest shareholder, Oxbridge Technology Partners, SA ("Oxbridge"), pursuant to which Oxbridge will acquire all of the rights to our current business operations through the purchase of all the shares of our two wholly owned subsidiaries, Shift It Media and General Aircraft, Inc. (the "Hive Out" Agreement). Under the Hive Out Agreement, Oxbridge will cancel its 100,000,000 Common Shares in exchange for: (a) the shares of our two subsidiaries, and (b) the payment of US$430,000 in cash, subject, among other things, to the Scheme becoming Effective. The assets and liabilities associated with such businesses will thereby be transferred to Oxbridge and Oxbridge's 100,000,000 Shares will be cancelled and returned to treasury once the Scheme becomes effective. Under the Scheme, we will issue to the XEN shareholders 56 shares of our common stock for each 175 shares of their common stock. This will result in our immediately issuing an expected total of 130,520,137 shares of our common stock to the XEN Shareholders, which, following our planned 10 to 1 reverse share split and the cancelation of the shares held by Oxbridge in the Hive Out Agreement, will represent over 97% of our issued and outstanding shares. 5 Table of Contents As an additional step toward completion of the Acquisition, our board of directors and a majority of our shareholders have approved a change in our corporate name to "Xenetic Biosciences, Inc." and a reverse split of our common stock on a 1 for 10 basis. In connection with the reverse split, the par value of our common stock will also be increased from $0.001 to $0.01 per share. The effective date of these changes in the U.S. over-the-counter securities markets is expected to be on or about January 14, 2014, pending final approval of their effectiveness by FINRA. In the event that the Acquisition is consummated, certain of the officers and directors of XEN will assume management of our company, and, upon the divestment of our aircraft and advertising subsidiaries, we will focus our business activities exclusively on the business of XEN. |
Posted at 18/7/2013 08:04 by buywell2 Worth a read Worth a read again cos I made a couple of mistakes Xenetic Biosciences expects higher rating from US switch Xenetic Biosciences (LON:XEN) is finally embarking on the process of "serious value" growth, according to its chief executive. This week Xenetic announced it is searching for a suitable candidate to reverse into to get a US listing, while the company's own development programmes for potential blockbuster drugs for western markets also starts soon. Chief executive Scott Maguire recently colourfully compared this process as being like a "battleship leaving the dock". He's referring to the first western clinical trial of ErepoXen for treating chronic anaemia, which is starting in Australia at the end of this month or next - one of several drugs in the firm's portfolio and a candidate that the firm wholly controls. Maguire explains that previously Xenetic has been purely research-based, relying on out-licensing partnerships and collaborations with groups in India and Russia. But, following a fundraising last year, the company has now begun the process of evolving into a drug developer, able to test and commercialise its own products. Maguire is so excited about this transition because, not only does if offer potentially large rewards for shareholders, but also because the firm's portfolio itself is highly promising. Xenetic specialises in developing orphan drugs for rare diseases, which have multi-billion dollar potential. Orphan drugs are fast-tracked to the market because they typically address diseases and conditions for which there are few, if any, medications. Now, following the firm's undeniable progress thus far, what is needed, is delivering on plans and, of course, securing financing, reckons Maguire. "As I see it, as management, the science is working and it's going to come down to a function of execution and money to deliver on the promise, because it's clear that these products we have in development have blockbuster potential and those are not my words, those are words from the investment and strategic community," he said. And Maguire highlighted all three of its technological platforms - PolyXen, ImuXen, OncoHist - have products in at least phase 2 clinical trials. Currently, its main focus is ErepoXen - the firm's most advanced product and likely to be the key share driver. Ironically, perhaps, this drug is one that does not fit into the firm's orphan strategy, in that it is a big, mass-market candidate. Maguire says the plan is to complete a dose finding study for western markets in December this year before striking a deal. "The goal of ErepoXen is to out-license as soon as allowable and there is already some interest in this product," he adds. "This is a big market drug, very expensive clinical trials, so we are going to be seeking a partner to out-license this as soon as we have data coming out of Australia/New Zealand. He said these locations were chosen because it is cost effective to run big market drug trials there, and the structure of the trials reflects the Food & Drug Administration (FDA) format so it's an easy transition into the US or Europe markets after phase 2 trials. Importantly, however, in Russia, where the drug is currently in trials, there is a chance to see revenues from ErepoXen sooner. In Russia, Xenetic hopes to see a commercial launch of the drug in the second half of next year and it will be receiving a 10% royalty on its sales in Russia. Another candidate the firm is excited about, and which will be added to its portfolio for the western markets, is OncoHist for acute myeloid leukaemia. Maguire told a conference call last month that he was "particularly" excited about this drug, which he said had "multi-billion dollar" potential. OnCoHist binds itself to leukaemia cells and leaves healthy cells alone, so there are no serious side effects. Maguire said a world-leading specialist described it as being the first novel mode of action for the disease he had seen in 20 years. The firm continues to test the efficacy of this drug and crucial phase 2 data is expected this summer. Part of the plans to expand into western markets is the move this September of staff to lab and development operations to Boston, USA - the world's leading centre for orphan drug development. Xenetic has also just announced it will look for a merger with an SEC reporting, unlisted US company, a move that will enable it get a quote on a major US stock market within a reasonable period. It wants to agree a deal in 2013, a move that will also see it de-list from AIM. Maguire said the long term benefits of being a US-centric organisation will become apparent as US markets give "significantly" greater value to firms like Xenetic with its broad proprietary drug pipeline. [...] buywell2 17 Jul'13 - 19:39 - 675 of 676 0 0 edit Thank you Earnest So to explain in more simple terms cos I am a tad thick at times I know and from some of the posts here several are a lot thicker than me. But since I have drawn the short straw in creating the thread I will put my spin on the last post .... This is MY take ....... 1. ErepoXen is due to start Phase 11 human trials in Australia IMMINENTLY even by the end of THIS MONTH ... which should attract a tad of XEN buying I would expect. 2. Interest from potential western partners has been EXPRESSED and they are tracking the data from these trials as they seek to DE-RISK themselves before committing spending a shedload of cash to take ErepoXen to the APPROVAL stage and then commercialize/advert 3. Meantime our Russian partners have started their OWN DOMESTIC RUSSIAN PHASE 111 trials and have dosed the first patient back in May 2013. 4. This means Xenetic has TWO CHANCES of scoring serious lolly on ErepoXen a) MEGABUCKS from a Western Capitalista deal after Phase 11 data gets released out of Australia , at which point I see one of the 'interested parties' getting the paper signed before someone else beats them to the punch ..... and b) Decent revenues to cover other drug developments in the pipeline from the 10% that Xenetic stand to get from ErepoXen sales in Russia when Phase 111 trials end and the state of Russia gives ErepoXen their approval .... which looks in my opinion to be VERY good when one remembers that EPO is not a new drug .... remember EPO has been used before but has gone out of patent. ErepoXen is NOT a step into the unknown for Xenetic. What Xenetic has done is to reformulate it and apply their own unique IP/ technology so that the drug works MUCH better than it ever did before , and one dose is efficacious for circa 1 MONTH. The data from the new trials SHOULD make ErepoXen the BEST performer on the marketplace V what's out there now. It is my opinion .... and remember I am a conservative sort of guy .... that the clever new guys recently taken on by Scott are going to use info and any EARLY indications from the trials to MAXIMISE XEN shareholder value when it comes to the reverse takeover/Shell deal in the USA. It is my considered opinion ..... and if you read my advfn posts ..... I consider much more than most posters ..... that WHOEVER gets to deal with XEN in the USA are going to make a MINT. |
Posted at 15/5/2013 07:34 by buywell2 pikersaFirst the USA 'listing' , the XEN RNS on 18th April said 'The Board of Xenetic Biosciences plc (the "Company" or "Xenetic") notes that its ordinary shares have been added to the list of cleared securities of the OTC Bulletin Board platform in the United States (U.S.), with stock reference XENEF, effective 16 April 2013. The Board wishes to state that no application has been made by the Company for the Company's shares to be added to this list. It appears that a US broker-dealer has made the application on behalf of one or more of its clients wishing to buy or sell, to enable trading of the Company's shares in the U.S.' Only 12 days later we had another RNS which stated ''Leading Biotech entrepreneur acquires interest in Pharmsynthez Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, announces that OPKO Health (NYSE: OPK) led by one of the world's leading bioentrepreneurs, Dr Phil Frost, has acquired a ten percent (10%) interest in one of Xenetic's strategic Russian partners, OAO Pharmsynthez ("Pharmasynthez")(MI It has been announced that OPKO and its partners will invest up to $60M in two stages to fund clinical development of Pharmsynthez candidates licensed in from XEN under its Co-Development Agreement ("CDA") completed in late 2009. This clinical data out of Russia is important to XEN in that the data will demonstrate whether or not a candidate is efficacious in humans. In addition, XEN is able to de-risk drug development by analysing the preclinical and clinical results from the Russian trials before pursuing further development of the same drug candidate in the rest of the world, including the US and EU. In accordance with the CDA completed in late 2009, Pharmsynthez is responsible for the development of six novel drug candidate drugs using two of Xenetic's patented technologies, PolyXen, for biologic, and ImuXen, for vaccine products. Under the CDA and as announced by Xenetic (then Lipoxen plc) on 16 November 2009, Xenetic owns all development, manufacturing and distribution rights for any candidates originating thereunder - including the cystic fibrosis drug, PulmoXen and the novel MS vaccine, MyeloXen - in all territories outside Russia and the former CIS, while equal such rights are held by Pharmsynthez for all Russia and Former CIS territories. Scott Maguire, CEO of Xenetic Biosciences said: "Phil Frost is one of the world's leading bioentrepreneurs has a long history of creating significant shareholder value. I have no doubt that Dr Frost and his team can assist Pharmsynthez in navigating the complex path to a drug's market launch. His company's investment in one of our most important partners can only serve to benefit Xenetic shareholders." Now it might well be that this Phil Frost had a hand in the USA listing ... be good if he did I reckon as it shows how much he rates XEN Technology I don't see any way XEN would not want shares traded in the UK AS WELL AS THE USA ..... because it's a WIN/WIN if we get good news re trials and contracts. Latest RNS's would indicate this to be the case XEN want to ATTRACT investors ... this will enhance shareholder value having DUAL listings does this. Shame it can't be TRIPLE. Expect more news soon |
Posted at 30/4/2013 10:28 by buywell2 This deal would seem to underpin the cash requirements for Pharmsynthez to undertake the clinical trials of the six new products that utilise Xenetic technologyThat such a guy stumps up the cash is promising and endorses what Xenetic provide . I guess this comes as a result of what is happening in the USA by the new XENETIC team Will OPKO take a stake in XEN I wonder Scott Maguire, CEO of Xenetic Biosciences said: "Phil Frost is one of the world's leading bioentrepreneurs has a long history of creating significant shareholder value. I have no doubt that Dr Frost and his team can assist Pharmsynthez in navigating the complex path to a drug's market launch. His company's investment in one of our most important partners can only serve to benefit Xenetic shareholders." 30 April 2013 Xenetic Biosciences plc Leading Biotech entrepreneur acquires interest in Pharmsynthez Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, announces that OPKO Health (NYSE: OPK) led by one of the world's leading bioentrepreneurs, Dr Phil Frost, has acquired a ten percent (10%) interest in one of Xenetic's strategic Russian partners, OAO Pharmsynthez ("Pharmasynthez")(MI It has been announced that OPKO and its partners will invest up to $60M in two stages to fund clinical development of Pharmsynthez candidates licensed in from XEN under its Co-Development Agreement ("CDA") completed in late 2009. This clinical data out of Russia is important to XEN in that the data will demonstrate whether or not a candidate is efficacious in humans. In addition, XEN is able to de-risk drug development by analysing the preclinical and clinical results from the Russian trials before pursuing further development of the same drug candidate in the rest of the world, including the US and EU. In accordance with the CDA completed in late 2009, Pharmsynthez is responsible for the development of six novel drug candidate drugs using two of Xenetic's patented technologies, PolyXen, for biologic, and ImuXen, for vaccine products. Under the CDA and as announced by Xenetic (then Lipoxen plc) on 16 November 2009, Xenetic owns all development, manufacturing and distribution rights for any candidates originating thereunder - including the cystic fibrosis drug, PulmoXen and the novel MS vaccine, MyeloXen in all territories outside Russia and the former CIS, while equal such rights are held by Pharmsynthez for all Russia and Former CIS territories. Scott Maguire, CEO of Xenetic Biosciences said: "Phil Frost is one of the world's leading bioentrepreneurs has a long history of creating significant shareholder value. I have no doubt that Dr Frost and his team can assist Pharmsynthez in navigating the complex path to a drug's market launch. His company's investment in one of our most important partners can only serve to benefit Xenetic shareholders." |
Posted at 23/6/2012 09:32 by buywell2 The present Chairman and CEO other big shareholders also thought Lipoxen was woth 13.5p a share when the company became Lipoxen see bottom of this post.Which is why I guess they were happy to buy more at 8.5p when more cash was needed and headway had been made with partners re trials and results of same. They obviously think the company is way undervalued now, when considering how far down the road some of the orphan drug candidates are , AND knowing via regular feedback from partners , how current trials are progressing ie positive news as these are NOT new compounds but are reformulated using Xenetic technology that has INCREASED the efficacy of the old drugs by a factor of MANY times PLUS getting BETTER results than other like drugs currently on the market. My guess is that the USA listing of XEN will acompany the results of Phase 2 trials from India and trial updates from Russia ''In furtherance of the US-based development plans, Xenetic Bioscience Inc was incorporated in May 2012 as the operating entity through which the new initiative will be executed.'' Such POSITIVE news should attract an INFLOW of new USA investors who for a change would not be buying into a dream as many venture capital funds seem to do there .... but buying into PROVEN TECHNOLOGY with POSITIVE TRIAL OUTCOMES . For example the following when presented in context with new positive trial data reults will score heavily New US patent for Lipoxen Lipoxen claims to have two 'potential blockbuster products' in developmentDrug developer Lipoxen has won a new US patent for its PolyXen protein-life extending technology. Based at the London Bioscience Innovation Centre, AIM-quoted Lipoxen says the US patent refers to the preparation of constructs related to PolyXen. Chief executive officer M Scott Maguire declares 'the new patent grant on this natural polymer which extends the life of protein supports our drive to become a leading innovator within the next generation of biologic drug space'. He says Lipoxen has two 'potential billion-dollar blockbuster products' in development, based on PolyXen technology. One is SuliXen, 'a long acting insulin', and the other is ErepoXen, 'a long acting erythropoietin' (EPO) to treat kidney failure. Who knows , the listing might even be accompanied with an announcement of the name of a NEW partner to take the drug into its final phase 3 trial and approval process. We are NOT talking years here .......... we are talking TWO MONTHS .... How can I say that ? Xenetic Biosciences doses its first intravenous patient with ErepoXen 13th Feb 2012, 8:16 am by Ian Lyall In total 40 chronic renal failure patients will be treated as part of the six-month phase I/IIa trial. The study is designed to confirm safety and reductions in the frequency of dosage, Xenetic said. Xenetic Biosciences (LON:XEN) said it and its partner, the Serum Institute of India, have dosed their first intravenous patient with ErepoXen, a potential long-acting treatment for anaemia. 6 months after 13th Feb 2012 is .................... Lucky for some I hope Although I don't think luck will come into it Xenetic's ErepoXen has already demonstrated in phase I and II(a) clinical trials based on the subcutaneous method of administration that it has the potential to be a long-acting version with a likely dosing profile of once per month. Xenetic chief executive Scott Maguire said: "The commencement of our IV patient trials in India with ErepoXen is an exciting step forward in combining the two methods of EPO administration. "We have previously announced positive Ph IIa subcutaneous results and now, with the intravenous trial, we cover the full $9 billion market potential of EPO. "We now have four drug candidates under clinical development with our partners including two via our recent acquisition of SymbioTec in Germany. Greenchip Investments plc (Incorporated and registered in England and Wales under the Companies Act 1985 with registered number 03213174) Proposed acquisition of Lipoxen Technologies Limited Proposed approval of waiver of Rule 9 of the City Code on Takeovers and Mergers Proposed Placing of 28,000,000 new Ordinary Shares at 13.5p per share Proposed change of name to Lipoxen plc and Application for re-admission to trading on AIM Nominated Adviser Grant Thornton Corporate Finance Broker Canaccord Capital (Europe) Limited Amount £5,000,000 SHARE CAPITAL IMMEDIATELY FOLLOWING ADMISSION Authorised Number of Ordinary Shares of Number of deferred shares 0.5p each of 0.01p each 673,300,000 16,335,000,000 Amount £2,148,333 Issued and fully paid Number of Number of Ordinary Shares of deferred shares 0.5p each of 0.01p each 102,966,665 16,335,000,000 The Placing Shares and Consideration Shares will, on Admission, rank pari passu in all respects with the existing Ordinary Shares and rank in full for all dividends and other distributions declared, made or paid on Ordinary Shares after Admission. It is expected that Admission will become effective and that dealings will commence in the Ordinary Shares on 17 January 2006. The Ordinary Shares have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or with any securities regulatory authority of any state or other jurisdiction of the United States or under the applicable securities laws of Australia, Canada, Japan, the Republic of South Africa or the Republic of Ireland. Subject to certain exceptions, the Ordinary Shares may not be offered or sold, directly or indirectly, in or into the United States, Australia, Canada, Japan, the Republic of South Africa or the Republic of Ireland or to or for the account or benefit of any national, resident or citizen of Australia, Canada, Japan, the Republic of South Africa or the Republic of Ireland or any person located in the United States. This document does not constitute an offer to issue or sell, or the solicitation of an offer to subscribe for or buy, any Ordinary Shares to any person in any jurisdiction to whom it is unlawful to make such offer or solicitation in such jurisdiction. Current Directors of the Company: Malcolm Alex Burne Colin William Hill Dr Giap Wang Chong All of 22 Melton Street, London NW1 2BW Proposed Directors upon Admission: Sir Brian Mansel Richards CBE, Non-executive Chairman Scott Maguire, Chief Executive Officer Professor Gregory Gregoriadis, Non-executive Director Dr Dmitry Dmitrievich Genkin, Non-executive Director Dr Tatiana Zhuravskaya, Non-executive Director |
Posted at 13/6/2012 10:47 by buywell2 Be nice if XEN utilize ADME Tox services from Cyprotex .... also now located in Watertown, Boston via the Apredica acquisition. 13 June 2012 Xenetic Biosciences plc ('Xenetic' or 'the Company') Xenetic Biosciences moves drug development program to Massachusetts Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, announces its formal decision to establish its new Drug Development Centre of Excellence in Massachusetts in an announcement coming in the run-up to the BIO 2012 International Convention being held in Boston June 18-21, 2012 at the Boston Convention & Exhibition Center, MA This announcement was first made by the Massachusetts Life Sciences Centre on 12 June 2012. Boston, June 12, 2012 -- Xenetic Biosciences plc ("Xenetic"/"XEN"/the "Company"), Governor Deval Patrick and the Massachusetts Life Sciences Center announced today that the UK-based, publicly-listed company plans to relocate its drug development operations to Massachusetts. Xenetic is a specialty drug development company with an extensive proprietary product pipeline with a primary focus on rare and orphan diseases. The Company is headquartered in London and, historically, has conducted all of its in-house optimisation and pre-clinical development work at its own laboratories. The relocation decision follows the March 2011 visit to the UK by Governor Patrick and a delegation of state leaders from industry, academia and government to promote mutually beneficial collaborations. The first discussion with Xenetic took place during that trade mission. The company intends to hire up to 6 employees in Massachusetts before the end of the year and has plans to build the new Drug Development Center to around 20 by the end of 2013. "Thanks to our investments in education, innovation and infrastructure, Massachusetts is a great place for international life sciences companies to do business," said Governor Patrick. "Stemming from last year's trade mission to the UK, we have worked closely with Xenetic to encourage them to come here and we look forward to seeing them create jobs and opportunities in the Commonwealth." In November 2011 Xenetic completed an important financing round and is now well-positioned to initiate a number of FDA/EMA clinical programs, a strategy that demands the bringing on board of a greatly expanded set of skills. Over the last 12 months the Company has evaluated a number of potential locations, and, while all sites offered some level of support, Management has concluded that Massachusetts can deliver the most comprehensive set of programs needed to facilitate the rapid establishment of its Drug Development Center of Excellence. The Company is currently working closely with the Massachusetts Life Sciences Center to facilitate these plans, targeting the opening of their new facility in the next few months - likely in the Waltham/Lexington area. M. Scott Maguire, a native of Boston and CEO of Xenetic, said: "Committing our company's entire drug development operations to Massachusetts is certainly a bold step but is surely one which presents an excellent opportunity to prove ourselves as a leading technology provider in the quest to develop better drug therapies which address areas of unmet need and confer genuine advantage to both patients and providers. We have worked closely with the Patrick Administration as we made this decision, and I have every confidence that the team in Massachusetts will be working with us every step of the way to maximize the likelihood of this being another great success for the Massachusetts supercluster!" With a focus on Orphan and Rare Disease drug development (for example, Xenetic's OncoHist® molecule has received designation as such from both the FDA and EMA) the Company believes that there is no region anywhere in the world that can currently compete with Massachusetts in the breadth of skills, experience and resources available to a company at this stage of its growth. Xenetic comes to Massachusetts with extensive technology offerings, each of which is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of the Company's product portfolio which is being built, currently, on three core technologies: PolyXen® for extending the efficacy and half life of biologic drugs OncoHist® for novel mode of action drugs for oncology therapies ImuXen® for creating new vaccines and improving existing vaccines The Company has multiple drug and vaccine programs with three products currently in human clinical development. A further key commercial stratagem is that, by means of reformulating existing APIs with their all-natural technologies, Xenetic is well-positioned to develop a broad range of bio-superior product candidates using both the PolyXen and ImuXen enabling platforms. The Company has broadened its portfolio of all-natural technologies through the acquisition in January 2012 of the OncoHist molecule. Xenetic will continue to seek new opportunities to extend its clinical reach into areas of high unmet need, whether through platform technologies or otherwise. The first step in establishing the Company's new Drug Development Centre of Excellence in Boston, was the Company's announcement in May 2012 of the appointment of Dr. Henry Hoppe IV as VP of Drug Development. Dr Hoppe is a leading biotechnology executive with over 20 years experience in drug development. Dr Hoppe's principal expertise lies in the processes surrounding regulatory submissions, IND filings and clinical trials, especially in the orphan and rare disease arena, exemplified in his 17 years at Genzyme Corporation where he was instrumental in the development and launch of many of their leading products. Dr. Hoppe has Inventor status on four US-granted patents addressing oncology diseases, anaemia and cystic fibrosis, each of which holds potential significance in Xenetic's development plan. Complementing Xenetic's presence in Boston, and being a strong advocate for the clinical development of OncoHist® in the USA in its primary indication of Acute Myeloid Leukemia, is Dr. Surender Kharbanda, who, since 1986, has held a number of research and academic positions at the Harvard Medical School and numerous scientific advisory board and executive level positions at Boston-based biotech companies focused on cancer drug development. With a track record of successful drug development, Dr. Kharbanda, who has worked at the Dana-Farber Cancer Institute and oncology-focused biotechnology companies on the molecular biology of human cancer and the development of anti-cancer agents for nearly 25 years, will be a key adviser to the Company as it establishes foundation contacts in the oncology field with both Key Opinion Leaders and with charitable foundations in the USA. Dr Kharbanda will be a member of the Company's Scientific Advisory Board. Xenetic will shortly be announcing the appointment of several new appointees to their SAB which will be a US-centric body with members drawn both from the commercial and academic worlds with a remit to deliver timely product and market focused strategies for the most effective application of capital into new development programs aimed at both delivering improved outcomes for patients and enhanced shareholder value for investors. Through the Massachusetts Life Sciences Center, Massachusetts is investing $1 billion over ten years in the growth of the state's life sciences supercluster. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Deval Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008. "We are excited to welcome Xenetic to the Massachusetts Life Sciences Supercluster," said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center. "Their presence here will contribute to our economy and strengthen our state's global leadership in the life sciences. I am confident that Xenetic will find all of the resources and partners that the company needs to grow and succeed right here in Massachusetts." "Massachusetts, a global leader in the life sciences, is proud to welcome Xenetic. Their decision to locate in Massachusetts is a clear reflection of the international strength and draw of the Commonwealth's innovation economy ecosystem and the success of the Administration's continued commitment to fostering a thriving life sciences supercluster," said Ken Brown, Executive Director of the Massachusetts Office of International Trade and Investment. "We congratulate Xenetic and look forward to partnering with them." The announcement comes as the state is preparing to host the 2012 BIO International Convention, being held June 18-21 at the Massachusetts Convention & Exhibition Center. The Convention provides state and industry leaders an opportunity to showcase Massachusetts as a great place to do business for international life sciences companies. "We are thrilled to welcome an innovative company like Xenetic to Massachusetts and look forward to working with their team to make them feel at home here," said MassBio President & CEO Robert K. Coughlin. "We know that international companies looking to grow in the United States will not find a more concentrated and diverse life sciences supercluster anywhere." |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
